Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 2, 2012, Pages 98-105

  Liu, Donghui ^a,b   Ji, Liang ^a   Wang, Yan ^b   Zheng, Lemin ^a  

^a Peking University Health Science Center   (China)

^b ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2 (COX 2); Endothelial cell; High density lipoprotein (HDL); Prostacyclin (PGI2)

Indexed keywords

ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; HIGH DENSITY LIPOPROTEIN; ICOSANOID; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE A2;

ACUTE CORONARY SYNDROME; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CHOLESTEROL TRANSPORT; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE AGGREGATION; UPREGULATION; VASOCONSTRICTION;

ANIMALS; CYCLOOXYGENASE 2; ENDOTHELIAL CELLS; EPOPROSTENOL; HUMANS; LIPOPROTEINS, HDL;

EID: 84874842587     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X11202020098     Document Type: Review

References (104)

1. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
2. Hansson, G.K. Inflammation, Atherosclerosis, and Coronary Artery Disease. N. Engl. J. Med., 2005, 352, 1685-1695.
3. Libby, P.; Aikawa, M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat. Med., 2002, 8, 1257-1262.
4. Ikuo, M. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat., 2002, 68-69: 165-175.
5. Hinz, B.; Brune, K., Cyclooxygenase-2-10 Years Later. J. Pharmacol. Exp. Ther., 2002, 300, 367-375.
6. Antman, E.M.; DeMets, D.; Loscalzo, J. Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation, 2005, 112, 759-770.
7. Patrono, C.; Garcia Rodriguez, L.A.; Landolfi, R.; Baigent, C. Low-Dose Aspirin for the Prevention of Atherothrombosis. N. Engl. J. Med., 2005, 353, 2373-2383.
8. Linton, M. F.; Fazio, S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol., 2004, 4, 116-123.
9. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R., Jr.; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989, 79, 8-15.
10. Kwiterovich, P.O., Jr., The antiatherogenic role of high-density lipoprotein cholesterol. Am. J. Cardiol., 1998, 82, 13Q-21Q.
11. Assmann, G.; Nofer, J.R. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med., 2003, 54, 321-341.
12. Cockerill, G.W.; Rye, K.A.; Gamble, J.R.; Vadas, M.A.; Barter, P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1987-1994.
13. Yuhanna, I.S.; Zhu, Y.; Cox, B.E.; Hahner, L.D.; Osborne-Lawrence, S.; Lu, P.; Marcel, Y. L.; Anderson, R.G.; Mendelsohn, M.E.; Hobbs, H.H.; Shaul, P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med., 2001, 7, 853-857.
14. O'Connell, B.J.; Genest, J., Jr. High-Density Lipoproteins and Endothelial Function. Circulation, 2001, 104, 1978-1983.
15. Norata, G.D.; Callegari, E.; Inoue, H.; Catapano, A.L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 871-877.
16. Mart́inez-González, J.; Escudero, I.; Badimon, L. Simvastatin potentiates PGI2 release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis, 2004, 174, 305-313.
17. Needleman, P.; Truk, J.; Jakschik, B.A.; Morrison, A.R.; Lefkowith, J.B. Arachidonic Acid Metabolism. Annu. Rev. Biochem., 1986, 55, 69-102.
18. Murakami, M.; Kambe, T.; Shimbara, S.; Kudo, I. Functional Coupling Between Various Phospholipase A2s and Cyclooxygenases in Immediate and Delayed Prostanoid Biosynthetic Pathways. J. Biol. Chem., 1999, 274, 3103-3115.
19. Williams, C.S.; DuBois, R.N. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol., 1996, 270, G393-400.
20. Luo, S.-F.; Wang, C.-C.; Chien, C.-S.; Hsiao, L.-D.; Yang, C.-M. Induction of cyclooxygenase-2 by lipopolysaccharide in canine tracheal smooth muscle cells: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-kB pathways. Cell Signal, 2003, 15, 497-509.
21. Yang, C.-M.; Chien, C.-S.; Hsiao, L.-D.; Luo, S.-F.; Wang, C.-C. Interleukin-1beta-induced cyclooxygenase-2 expression is mediated through activation of p42/44 and p38 MAPKS, and NFkB pathways in canine tracheal smooth muscle cells. Cell Signal, 2002, 14, 899-911.
22. FitzGerald, G.A, Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am. J. Cardiol., 2002, 89, 26-32.
23. Cheng, Y.; Austin, S.C.; Rocca, B.; Koller, B.H.; Coffman, T.M.; Grosser, T.; Lawson, J.A.; FitzGerald, G.A. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2. Science, 2002, 296, 539-541.
24. Catella-Lawson, F.; Crofford, L.J. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med., 2001, 110, 28-32.
25. Kobayashi, T.; Tahara, Y.; Matsumoto, M.; Iguchi, M.; Sano, H.; Murayama, T.; Arai, H.; Oida, H.; Yurugi-Kobayashi, T.; Yamashita, J. K.; Katagiri, H.; Majima, M.; Yokode, M.; Kita, T.; Narumiya, S. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest., 2004, 114, 784-794.
26. Pratico, D.; Tillmann, C.; Zhang, Z.-B.; Li, H.; FitzGerald, G. A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. USA, 2001, 98, 3358-3363.
27. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A.; the Adenomatous Polyp Prevention on Vioxx Trial, I., Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N. Engl. J. Med., 2005, 352, 1092-1102.
28. Schonbeck, U.; Sukhova, G.K.; Graber, P.; Coulter, S.; Libby, P. Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions. Am. J. Pathol., 1999, 155, 1281-1291.
29. Cipollone, F.; Prontera, C.; Pini, B.; Marini, M.; Fazia, M.; De Cesare, D.; Iezzi, A.; Ucchino, S.; Boccoli, G.; Saba, V.; Chiarelli, F.; Cuccurullo, F.; Mezzetti, A. Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability. Circulation, 2001, 104, 921-927.
30. Baker, C.S.R.; Hall, R.J.C.; Evans, T.J.; Pomerance, A.; Maclouf, J.; Creminon, C.; Yacoub, M.H.; Polak, J.M. Cyclooxygenase-2 Is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalizes With Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in Macrophages. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 646-655.
31. Paramo, J. A.; Rodriguez, J. A.; Beloqui, O.; Orbe, J., Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis? Curr. Drug Targets Cardiovasc. Haematol. Disord., 2005, 5, 303-311.
32. Ariasnegrete, S.; Keller, K.; Chadee, K. Proinflammatory Cytokines Regulate Cyclooxygenase-2 mRNA Expression in Human Macrophages. Biochem. Biophys. Res. Commun., 1995, 208, 582-589.
33. Ejima, K.; Layne, M.D.; Carvajal, I.M.; Kritek, P.A.; Baron, R.M.; Chen, Y.-H.; Vom Saal, J.; Levy, B.D.; Yet, S.-F.; Perrella, M.A. Cyclooxygenase-2-deficient mice are resistant to endotoxininduced inflammation and death. FASEB J., 2003, 17, 1325-1327.
34. Tuo, J.; Tuaillon, N.; Shen, D.; Chan, C.-C. Endotoxin-Induced Uveitis in Cyclooxygenase-2-deficient Mice. Invest. Ophthalmol. Vis. Sci., 2004, 45, 2306-2313.
35. Caughey, G.E.; Cleland, L.G.; Penglis, P.S.; Gamble, J.R.; James, M.J. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J. Immunol., 2001, 167, 2831-2838.
36. Debabrata, M., Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol., 2002, 63, 817-821.
37. Thomas, D.W.; Mannon, R.B.; Mannon, P.J.; Latour, A.; Oliver, J.A.; Hoffman, M.; Smithies, O.; Koller, B.H.; Coffman, T.M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest., 1998, 102, 1994-2001.
38. Egan, K.M.; Lawson, J.A.; Fries, S.; Koller, B.; Rader, D.J.; Smyth, E.M.; FitzGerald, G. A. COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice. Science, 2004, 306, 1954-1957.
39. Murata, T.; Ushikubi, F.; Matsuoka, T.; Hirata, M.; Yamasaki, A.; Sugimoto, Y.; Ichikawa, A.; Aze, Y.; Tanaka, T.; Yoshida, N.; Ueno, A.; Oh-ishi, S.; Narumiya, S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 1997, 388, 678-682.
40. Topper, J.N.; Cai, J.; Falb, D.; Gimbrone, M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA, 1996, 93, 10417-10422.
41. Zembowicz, A.; Jones, S.L.; Wu, K.K. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J. Clin. Invest., 1995, 96, 1688-1692.
42. Masferrer, J.L.; Zweifel, B.S.; Manning, P.T.; Hauser, S.D.; Leahy, K.M.; Smith, W. G.; Isakson, P.C.; Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA., 1994, 91, 3228-3232.
43. Baigent, C.; Patrono, C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. ArArthritis. Rheum., 2003, 48, 12-20.
44. Buerkle, M.A.; Lehrer, S.; Sohn, H.-Y.; Conzen, P.; Pohl, U.; Krotz, F. Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo. Circulation, 2004, 110, 2053-2059.
45. Chenevard, R.; Hurlimann, D.; Bechir, M.; Enseleit, F.; Spieker, L.; Hermann, M.; Riesen, W.; Gay, S.; Gay, R. E.; Neidhart, M.; Michel, B.; Luscher, T. F.; Noll, G.; Ruschitzka, F. Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease. Circulation, 2003, 107, 405-409.
46. Burleigh, M.E.; Babaev, V. R.; Oates, J. A.; Harris, R.C.; Gautam, S.; Riendeau, D.; Marnett, L.J.; Morrow, J.D.; Fazio, S.; Linton, M.F. Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor-deficient Mice. Circulation, 2002, 105, 1816-1823.
47. Hennan, J.K.; Huang, J.; Barrett, T.D.; Driscoll, E.M.; Willens, D.E.; Park, A.M.; Crofford, L.J.; Lucchesi, B.R. Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries. Circulation, 2001, 104, 820-825.
48. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
49. Solomon, S.D.; McMurray, J.J.V.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N. Engl. J. Med., 2005, 352, 1071-1080.
50. Grosser, T.; Fries, S.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest., 2006, 116, 4-15.
51. McAdam, B.F.; Catella-Lawson, F.; Mardini, I.A.; Kapoor, S.; Lawson, J.A.; FitzGerald, G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA., 1999, 96, 272-277.
52. Catella-Lawson, F.; McAdam, B.; Morrison, B.W.; Kapoor, S.; Kujubu, D.; Antes, L.; Lasseter, K.C.; Quan, H.; Gertz, B.J.; Fitzgerald, G.A. Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids. J. Pharmacol. Exp. Ther., 1999, 289, 735-741.
53. Nicholas A F., Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci., 2007, 28, 106-110.
54. Gleim, S.; Kasza, Z.; Martin, K.; Hwa, J. Prostacyclin receptor/ thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr. Atheroscler. Rep., 2009, 11, 227-235.
55. Helliwell, R.J.A.; Adams, L.F.; Mitchell, M.D. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids, 2004, 70, 101-113.
56. Kerry-Anne, R.; Moira, A.C.; Philip, J.B. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis, 1999, 145, 227-238.
57. Vaisar, T.; Pennathur, S.; Green, P.S.; Gharib, S.A.; Hoofnagle, A.N.; Cheung, M.C.; Byun, J.; Vuletic, S.; Kassim, S.; Singh, P.; Chea, H.; Knopp, R.H.; Brunzell, J.; Geary, R.; Chait, A.; Zhao, X.Q.; Elkon, K.; Marcovina, S.; Ridker, P.; Oram, J.F.; Heinecke, J.W. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest., 2007, 117, 746-756.
58. Navab, M.; Berliner, J.A.; Subbanagounder, G.; Hama, S.; Lusis, A.J.; Castellani, L. W.; Reddy, S.; Shih, D.; Shi, W.; Watson, A.D.; Van Lenten, B.J.; Vora, D.; Fogelman, A.M. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 481-488.
59. Van Lenten, B.J.; Navab, M.; Shih, D.; Fogelman, A.M.; Lusis, A.J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med., 2001, 11, 155-161.
60. Calabresi, L.; Gomaraschi, M.; Franceschini, G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1724-1731.
61. Suc, I.; Escargueil-Blanc, I.; Troly, M.; Salvayre, R.; Negre-Salvayre, A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2158-2166.
62. Sugano, M.; Tsuchida, K.; Makino, N., High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-[alpha]-Induced Apoptosis. Biochem Biophys Res Commun 2000, 272, 872-876.
63. Nofer, J.R.; Levkau, B.; Wolinska, I.; Junker, R.; Fobker, M.; von Eckardstein, A.; Seedorf, U.; Assmann, G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem., 2001, 276, 34480-34485.
64. Seetharam, D.; Mineo, C.; Gormley, A.K.; Gibson, L.L.; Vongpatanasin, W.; Chambliss, K.L.; Hahner, L.D.; Cummings, M.L.; Kitchens, R.L.; Marcel, Y.L.; Rader, D.J.; Shaul, P.W. Highdensity lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res., 2006, 98, 63-72.
65. Kimura, T.; Sato, K.; Malchinkhuu, E.; Tomura, H.; Tamama, K.; Kuwabara, A.; Murakami, M.; Okajima, F. High-Density Lipoprotein Stimulates Endothelial Cell Migration and Survival Through Sphingosine 1-Phosphate and Its Receptors. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1283-1288.
66. Ashby, D.T.; Rye, K.-A.; Clay, M.A.; Vadas, M.A.; Gamble, J.R.; Barter, P.J. Factors Influencing the Ability of HDL to Inhibit Expression of Vascular Cell Adhesion Molecule-1 in Endothelial Cells. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1450-1455.
67. Dimayuga, P.; Zhu, J.; Oguchi, S.; Chyu, K.Y.; Xu, X. O.; Yano, J.; Shah, P.K.; Nilsson, J.; Cercek, B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun., 1999, 264, 465-468.
68. Cockerill, G.W.; Huehns, T.Y.; Weerasinghe, A.; Stocker, C.; Lerch, P.G.; Miller, N.E.; Haskard, D.O. Elevation of plasma highdensity lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 2001, 103, 108-112.
69. Nofer, J.R.; van der Giet, M.; Tolle, M.; Wolinska, I.; von Wnuck Lipinski, K.; Baba, H. A.; Tietge, U.J.; Godecke, A.; Ishii, I.; Kleuser, B.; Schafers, M.; Fobker, M.; Zidek, W.; Assmann, G.; Chun, J.; Levkau, B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004, 113, 569-581.
70. Ramet, M.E.; Ramet, M.; Lu, Q.; Nickerson, M.; Savolainen, M.J.; Malzone, A.; Karas, R.H. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol., 2003, 41, 2288-2297.
71. Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res., 2006, 98, 1352-1364.
72. Fleisher, L.N.; Tall, A.R.; Witte, L.D.; Miller, R.W.; Cannon, P.J. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J. Biol. Chem., 1982, 257, 6653-6655.
73. Pomerantz, K.B.; Fleisher, L.N.; Tall, A.R.; Cannon, P.J. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J. Lipid Res., 1985, 26, 1269-1276.
74. Tamagaki, T.; Sawada, S.; Imamura, H.; Tada, Y.; Yamasaki, S.; Toratani, A.; Sato, T.; Komatsu, S.; Akamatsu, N.; Yamagami, M.; Kobayashi, K.; Kato, K.; Yamamoto, K.; Shirai, K.; Yamada, K.; Higaki, T.; Nakagawa, K.; Tsuji, H.; Nakagawa, M. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis, 1996, 123, 73-82.
75. Van Sickle, W.A.; Wilcox, H.G.; Malik, K.U.; Nasjletti, A. High density lipoprotein-induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization. J. Lipid Res., 1986, 27, 517-522.
76. Cockerill, G.W.; Saklatvala, J.; Ridley, S.H.; Yarwood, H.; Miller, N.E.; Oral, B. Nithyanathan, S.; Taylor, G.; Haskard, D. O., High-Density Lipoproteins Differentially Modulate Cytokine-Induced Expression of E-Selectin and Cyclooxygenase-2. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 910-917.
77. Yamamoto, K.; Arakawa, T.; Ueda, N.; Yamamoto, S. Transcriptional Roles of Nuclear Factor B and Nuclear Factor-Interleukin-6 in the Tumor Necrosis Factor-Dependent Induction of Cyclooxygenase-2 in MC3T3-E1 Cells. J. Biol. Chem., 1995, 270, 31315-31320.
78. Crofford, L.J.; Tan, B.; McCarthy C.J.; Hla, T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis. Rheum., 1997, 40, 226-236.
79. Park, S.-H.; Park, J.H. Y.; Kang, J.-S.; Kang, Y.-H., Involvement of transcription factors in plasma HDL protection against TNFalpha-induced vascular cell adhesion molecule-1 expression. Int. J. Biochem. Cell Biol., 2003, 35, 168-182.
80. Xia, P.; Vadas, M.A.; Rye, K.-A.; Barter, P.J.; Gamble, J.R. High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem., 1999, 274, 33143-33147.
81. Vinals, M.; Martinez-Gonzalez, J.; Badimon, L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2405-2411.
82. Liu, D.; Ji, L.; Tong, X.; Pan, B.; Han, J.-Y.; Huang, Y.; Chen, Y. E.; Pennathur, S.; Zhang, Y.; Zheng, L. Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am. J. Physiol. Cell Physiol., 2011, 301, C739-C748.
83. LaPointe, M. C.; Isenovic, E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension, 1999, 33, 276-282.
84. Callegari, E.; Norata, G.D.; Inoue, H.; Catapano, A.L. Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. Int. J. Mol. Med., 2006, 18, 209-213.
85. Smith, L.H.; Boutaud, O.; Breyer, M.; Morrow, J.D.; Oates, J.A.; Vaughan, D.E. Cyclooxygenase-2-Dependent Prostacyclin Formation Is Regulated by Low Density Lipoprotein Cholesterol In Vitro. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 983-988.
86. Degraeve, F.; Bolla, M.; Blaie, S.; Creminon, C.; Quere, I.; Boquet, P.; Levy-Toledano, S.; Bertoglio, J.; Habib, A. Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells. Involvement of Geranylgeranylated Proteins. J. Biol. Chem., 2001, 276, 46849-46855.
87. Rauramaa, R.; Salonen, J.T.; Kukkonen-Harjula, K.; Seppanen, K.; Seppala, E.; Vapaatalo, H.; Huttunen, J.K. Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid: a controlled randomised trial in middle aged men. Br. Med. J. (Clin Res Ed), 1984, 288, 603-606.
88. Symons, J.D. Longitudinal and cross-sectional studies of the relationship between 6-keto PGF1 alpha and high density lipoproteins. Prostaglandins Leukot Essent Fatty Acids, 1990, 39, 159-165.
89. Yui, Y.; Aoyama, T.; Morishita, H.; Takahashi, M.; Takatsu, Y.; Kawai, C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J. Clin. Invest., 1988, 82, 803-807.
90. Eisenberg, S. High density lipoprotein metabolism. J. Lipid Res., 1984, 25, 1017-1058.
91. Norata, G.D.; Catapano, A.L. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc. Health Risk Manag., 2005, 1, 119-129.
92. Okajima, F., Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta, 2002, 1582, 132-137.
93. Kimura, T.; Sato, K.; Kuwabara, A.; Tomura, H.; Ishiwara, M.; Kobayashi, I.; Ui, M.; Okajima, F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem., 2001, 276, 31780-31785.
94. Argraves, K.M.; Argraves, W.S.,HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res., 2007, 48, 2325-2333.
95. Rodriguez, C.; Gonzalez-Diez, M.; Badimon, L.; Martinez-Gonzalez, J. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost., 2009, 101, 665-673.
96. Gonzalez-Diez, M.; Rodriguez, C.; Badimon, L.; Martinez-Gonzalez, J. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb. Haemost., 2008, 100, 119-126.
97. Nodai, A.; Machida, T.; Izumi, S.; Hamaya, Y.; Kohno, T.; Igarashi, Y.; Iizuka, K.; Minami, M.; Hirafuji, M. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci., 2007, 80, 1768-1776.
98. Damirin, A.; Tomura, H.; Komachi, M.; Tobo, M.; Sato, K.; Mogi, C.; Nochi, H.; Tamoto, K.; Okajima, F. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol. Pharmacol., 2005, 67, 1177-1185.
99. Kim, J.I.; Jo, E.J.; Lee, H.Y.; Cha, M.S.; Min, J.K.; Choi, C.H.; Lee, Y.M.; Choi, Y.A.; Baek, S.H.; Ryu, S.H.; Lee, K.S.; Kwak, J.Y.; Bae, Y.S. Sphingosine 1-phosphate in amniotic fluid modulates cyclooxygenase-2 expression in human amnion-derived WISH cells. J. Biol. Chem., 2003, 278, 31731-31736.
100. Riederer, M.; Ojala, P.J.; Hrzenjak, A.; Graier, W.F.; Malli, R.; Tritscher, M.; Hermansson, M.; Watzer, B.; Schweer, H.; Desoye, G.; Heinemann, A.; Frank, S. Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production. J. Lipid Res., 2010, 51, 2957-2966.
101. Escudero, I.; Martínez-González, J.; Alonso, R.; Mata, P.; Badimon, L. Experimental and interventional dietary study in humans on the role of HDL fatty acid composition in PGI2 release and Cox-2 expression by VSMC. Eur. J. Clin. Invest., 2003, 33, 779-786.
102. Kothapalli, D.; Fuki, I.; Ali, K.; Stewart, S.A.; Zhao, L.; Yahil, R.; Kwiatkowski, D.; Hawthorne, E.A.; FitzGerald, G.A.; Phillips, M.C.; Lund-Katz, S.; Pure, E.; Rader, D.J.; Assoian, R.K. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J. Clin. Invest., 2004, 113, 609-618.
103. Calleros, L.; Lasa, M.; Toro, M.J.; Chiloeches, A. Low cell cholesterol levels increase NFkappaB activity through a p38 MAPK-dependent mechanism. Cell Signal, 2006, 18, 2292-2301.
104. Furuchi, T.; Anderson, R.G. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem., 1998, 273, 21099-21104.